



Jay Michael S. Balagtas

Clinical Professor, Pediatrics - Hematology & Oncology

CLINICAL OFFICE (PRIMARY)

- **Oncology**

750 Welch RD STE 200

Palo Alto, CA 94304

Tel (650) 723-5535 Fax (650) 723-5231

Bio

CLINICAL FOCUS

- Ped Hematology/Oncology
- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Clinical Professor, Pediatrics - Hematology & Oncology

PROFESSIONAL EDUCATION

- Medical Education: New York Medical College (1998) NY
- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2009) CA
- Residency: United States Naval Medical Center San Diego Pediatric Residency (2003) CA
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)

Research & Scholarship

CLINICAL TRIALS

- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT, Recruiting
- A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma, Recruiting
- A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG), Recruiting
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma, Recruiting
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL), Recruiting
- A Study to Give Treatment Inside the Eye to Treat Retinoblastoma, Recruiting
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma, Recruiting
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours, Recruiting
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors, Recruiting

- Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma, Recruiting
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma, Recruiting
- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG), Recruiting
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy, Recruiting
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia, Recruiting
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma, Recruiting
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL), Recruiting
- Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma, Recruiting
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia, Not Recruiting
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery, Not Recruiting
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT, Not Recruiting
- A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment, Not Recruiting
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma, Not Recruiting
- A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma, Not Recruiting
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma, Not Recruiting
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia, Not Recruiting
- A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor, Not Recruiting
- Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement, Not Recruiting
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma, Not Recruiting
- Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors, Not Recruiting
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia, Not Recruiting
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Not Recruiting
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Not Recruiting
- Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma, Not Recruiting
- Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma, Not Recruiting
- Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma, Not Recruiting
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors, Not Recruiting
- Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia, Not Recruiting
- Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET, Not Recruiting
- Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors, Not Recruiting
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery, Not Recruiting
- Collecting and Storing Biological Samples From Patients With Ewing Sarcoma, Not Recruiting

- Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer, Not Recruiting
- Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma, Not Recruiting
- Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma, Not Recruiting
- Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma, Not Recruiting
- Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma, Not Recruiting
- Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma, Not Recruiting
- Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor, Not Recruiting
- Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma, Not Recruiting
- Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma, Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes, Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia, Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations, Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma, Not Recruiting
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma, Not Recruiting
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma, Not Recruiting
- Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor, Not Recruiting
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma, Not Recruiting
- Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma, Not Recruiting
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma, Not Recruiting
- Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma, Not Recruiting
- Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma, Not Recruiting
- Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma, Not Recruiting
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma, Not Recruiting
- Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia, Not Recruiting
- Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma, Not Recruiting
- Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group, Not Recruiting
- Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors, Not Recruiting
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Not Recruiting
- Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation, Not Recruiting

- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma, Not Recruiting
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma, Not Recruiting
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma, Not Recruiting
- Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma, Not Recruiting
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies, Not Recruiting
- Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma, Not Recruiting
- Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor, Not Recruiting
- Neuropsychological and Behavioral Testing in Younger Patients With Cancer, Not Recruiting
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma, Not Recruiting
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas, Not Recruiting
- Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients., Not Recruiting
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL), Not Recruiting
- Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors, Not Recruiting
- Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia, Not Recruiting
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma, Not Recruiting
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma, Not Recruiting
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Not Recruiting
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma, Not Recruiting
- Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer, Not Recruiting
- Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder, Not Recruiting
- Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia, Not Recruiting
- Study of Blood Samples From Newborns With Down Syndrome, Not Recruiting
- Study of Kidney Tumors in Younger Patients, Not Recruiting
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors, Not Recruiting
- Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission, Not Recruiting
- Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors, Not Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial), Not Recruiting
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia, Not Recruiting

- Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia, Not Recruiting
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations, Not Recruiting
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma, Not Recruiting
- Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor, Not Recruiting
- Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma, Not Recruiting
- Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma, Not Recruiting
- Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer, Not Recruiting
- Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial), Not Specified

Publications

PUBLICATIONS

- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**
Mak, B., Tran, B., Thomas, H., Walker, R., Pashankar, F., Feldman, D., Hansen, A., Huddart, R., Dunwoodie, E., Wheeler, M., Stevanovic, A., Mazhar, D., Lawrence, et al
LIPPINCOTT WILLIAMS & WILKINS.2026: TPS623
- **Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results**
Schultz, L., Aftandilian, C., Baggott, C., Corwin, N., Fujimoto, M., Li, A., Mavroukakis, S., Moon, J., Sahaf, B., Jacobs, A., Mendoza, C., Levenson, A., Frank, et al
ELSEVIER.2025: 2374
- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**
Mak, B., Tran, B., Thomas, H., Pashankar, F. D., Hansen, A., Feldman, D. R., Huddart, R. A., Wheeler, M., Dunwoodie, E., Mazhar, D., Lawrence, N., Stevanovic, A., Birtle, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS653
- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**
Mak, B., Tran, B., Pashankar, F. D., Mazhar, D., Huddart, R. A., Wheeler, M., Walpole, E., Feldman, D. R., Dunwoodie, E., Lawrence, N., Birtle, A., Wyld, D., Stevanovic, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: TPS524
- **Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.** *Frontiers in immunology*
Johns, C., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Dagher, R., Nadel, H., Balagtas, J., Aftandilian, C., Ramakrishna, S., Lacayo, N., Davis, K. L., Stieglitz, et al
2024; 15: 1423487
- **A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia**
Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y.
SPRINGER/PLENUM PUBLISHERS.2021: S55
- **P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).**
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, et al
LIPPINCOTT WILLIAMS & WILKINS.2021

- **P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)**
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F., Tran, B., Jeffery, M., Mazhar, D., Huddart, R., Walpole, E., Stevanovic, A. G., Wyld, D., Hanning, et al
WILEY.2020: 205-206
- **The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH** *JOURNAL OF THROMBOSIS AND HAEMOSTASIS*
Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm
2018; 16 (1): 175–80
- **Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy** *JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY*
Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y.
2016; 14 (8): 337–41
- **Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting** *PEDIATRIC BLOOD & CANCER*
Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P.
2015; 62 (11): 2025-2028
- **Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.** *PLoS genetics*
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, et al
2013; 9 (4)
- **Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis** *PEDIATRIC BLOOD & CANCER*
Balagtas, J. M., Dahl, G. V.
2012; 58 (1): 101-103
- **Liposomal amphotericin B associated with severe hyperphosphatemia** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M.
2008; 27 (1): 77-79